Phase 2
Completed N=16
Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Left Ventricle Function
Source: ClinicalTrials.gov NCT00748982 ↗
Enrolled (actual)
16
Serious AEs
—
Results posted
Jun 2011
Primary outcomePrimary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
Summary
To explore if AZD1305 compromises left ventricular performance in patients with left ventricular dysfunction
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Left Ventricular Ejection Fraction (LVEF), Change From Baseline |
2.00; -3.25 | — |
| SECONDARY Number of Subjects With at Least One Reported Adverse Event During Each Study Period and in Each Dose Group |
0; 0 | — |
| SECONDARY Area Under Curve (AUC) ( µmol*h/L) of AZD1305 |
2.04 | — |
| SECONDARY QTcF Interval |
446; 445 | — |
Eligibility Criteria
Inclusion Criteria
- Male patients and postmenopausal women
- Mildly/moderately decreased heart function
- Regular heart rhythm
Exclusion Criteria
- Potassium outside normal reference values
- Child bearing potential
- Severely decreased heart function
Data sourced from ClinicalTrials.gov (NCT00748982). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.